Company intelligence / Profile preview

Guangxi Zhongheng Innovative Medicine Research

Ownership: Private
Development stage: Other

Overview

Subsidiary or R&D entity contributing to Guangxi Wuzhou Zhongheng Group’s portfolio. The group (through various subsidiaries) develops and produces generics and branded pharmaceuticals, with approvals in oncology and anti-infectives. Projects include small molecule chemotherapeutics, vaccines, and live biotherapeutics; some are nationally approved in China, with additional global development via international partners.

Therapeutic areas: Infectious DiseasesOncologyWomen's Health
Modalities: Small moleculeProbioticsCell therapyTherapeutic vaccineChemical drug
Industry: Biotech

Drug pipeline

1 asset

Shenqi Yanshen Keli

Unknown

Partnerships

DelMar Pharmaceuticals (development and supply of VAL-083/dianhydrodulcitol for oncology use in China and globally)

Beyond the preview

Go deeper on Guangxi Zhongheng Innovative Medicine Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangxi Zhongheng Innovative Medicine Research.

Explore the full profile